Abstract
Glioblastoma (GBM) is the most common malignant primary brain tumor in adults. Despite therapy with surgery, radiation and chemotherapy, the prognosis remains poor, and the demand for more effective treatments is high. Research has increased our understanding of the molecular pathways important for gliomagenesis and disease progression, including the epidermal growth factor receptor (EGFR) and downstream phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway. Targeted therapeutics have been developed against these receptors and pathways. This article will review the rationale and current evidence for inhibitors of this signaling axis.
Keywords: Glioblastoma, EGFR inhibitors, mTOR inhibitors, treatments, review, chemotherapy, disease, Epidermal growth, phosphatidylinositol, mammalian target, rapamycin, high frequency, phenotype, tyrosine, chromosome, glycoprotein, cell, protein kinase C, tumor proliferation, exons, ligand binding, immunohistochemistry, antibodies, vaccines, glioma, oral, tissue, phosphorylation, hepatic enzyme system, cetuximab, solubility, blood concentration ratios, liver, hybridization, dose, enzyme, anti-epileptic, vaccine, mutations, tumor, temsirolimus, cholesterolemia, lymphopenia, tyrosine kinase receptor
Current Cancer Therapy Reviews
Title: Targeting the Epidermal Growth Factor Pathway as Therapy for Glioblastoma
Volume: 7 Issue: 1
Author(s): Eudocia C. Quant, Catherine L. Nutt, Daphne Wang and Tracy T. Batchelor
Affiliation:
Keywords: Glioblastoma, EGFR inhibitors, mTOR inhibitors, treatments, review, chemotherapy, disease, Epidermal growth, phosphatidylinositol, mammalian target, rapamycin, high frequency, phenotype, tyrosine, chromosome, glycoprotein, cell, protein kinase C, tumor proliferation, exons, ligand binding, immunohistochemistry, antibodies, vaccines, glioma, oral, tissue, phosphorylation, hepatic enzyme system, cetuximab, solubility, blood concentration ratios, liver, hybridization, dose, enzyme, anti-epileptic, vaccine, mutations, tumor, temsirolimus, cholesterolemia, lymphopenia, tyrosine kinase receptor
Abstract: Glioblastoma (GBM) is the most common malignant primary brain tumor in adults. Despite therapy with surgery, radiation and chemotherapy, the prognosis remains poor, and the demand for more effective treatments is high. Research has increased our understanding of the molecular pathways important for gliomagenesis and disease progression, including the epidermal growth factor receptor (EGFR) and downstream phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway. Targeted therapeutics have been developed against these receptors and pathways. This article will review the rationale and current evidence for inhibitors of this signaling axis.
Export Options
About this article
Cite this article as:
C. Quant Eudocia, L. Nutt Catherine, Wang Daphne and T. Batchelor Tracy, Targeting the Epidermal Growth Factor Pathway as Therapy for Glioblastoma, Current Cancer Therapy Reviews 2011; 7 (1) . https://dx.doi.org/10.2174/157339411794474146
DOI https://dx.doi.org/10.2174/157339411794474146 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Discovering Tumor Suppressor Genes Through Genome-Wide Copy Number Analysis
Current Genomics Apoptosis Pathways and Neuroblastoma Therapy
Current Pharmaceutical Design Therapeutic Targeting of Malignant Glioma
Anti-Cancer Agents in Medicinal Chemistry Identification of Glioma Specific Genes as Diagnostic and Prognostic Markers for Glioma
Current Bioinformatics Antigenic Differences Between Normal and Malignant Cells as a Basis for Treatment of Intracerebral Neoplasms Using a DNA-Based Vaccine
Current Genomics Peptide Activators of the p53 Tumor Suppressor
Current Pharmaceutical Design Role of GSK-3 in Cardiac Health: Focusing on Cardiac Remodeling and Heart Failure
Current Drug Targets Anticancer Drug Design Using Scaffolds of β-Lactams, Sulfonamides, Quinoline, Quinoxaline and Natural Products. Drugs Advances in Clinical Trials
Current Medicinal Chemistry Structure of the Epidermal Growth Factor Receptor Gene and Intron Recombination in Human Gliomas
Current Genomics Manipulation of Glycolysis in Malignant Tumors: Fantasy or Therapy?
Current Medicinal Chemistry Computational Analysis of miRNA and their Gene Targets Significantly Involved in Colorectal Cancer Progression
MicroRNA The History of the HSV Amplicon: From Naturally Occurring Defective Genomes to Engineered Amplicon Vectors
Current Gene Therapy Cancer Stem Cells and the Biology of Brain Tumors
Current Stem Cell Research & Therapy Targeting AMPK Signaling Pathway to Overcome Drug Resistance for Cancer Therapy
Current Drug Targets Natural Proteinaceous Inhibitors of Serine Proteases
Current Pharmaceutical Design Design and Virtual Screening Towards Synthesis of Novel Substituted Thiosemicarbozones as Ribonuleotide Reductase (RNR) Inhibitors with Improved Cellular Trafficking and Anticancer Activity
Current Topics in Medicinal Chemistry Safety and Utilization of Blood Components as Therapeutic Delivery Systems
Current Pharmaceutical Biotechnology Scope of Lipid Nanoparticles in Neuroscience: Impact on the Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design Opioid Withdrawal Syndrome: Emerging Concepts and Novel Therapeutic Targets
CNS & Neurological Disorders - Drug Targets Role of Glucocorticoids in Breast Cancer
Current Pharmaceutical Design